The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women
Open accessAbstract
Cytological cervical screening is rather inefficient because of relatively high proportions of false negative and false positive smears. To evaluate the efficiency of high‐risk human papillomavirus (hrHPV) testing, by GP5+/6+ PCR‐enzyme immunoassay (EIA), in conjunction with cytology (Intervention Group) to that of the classical cytology (Control Group), we initiated the Population Based Screening Study Amsterdam (POBASCAM). POBASCAM is a population‐based randomized controlled trial for implementation of hrHPV testing in cervical screening. The outcome measure is the proportion of histologically confirmed ≥CIN3 lesions in each study arm up to and including the next screening round after 5 years. We present the design, methods and baseline data of POBASCAM. When, in the next 5 years, the follow‐up will be completed, the data obtained will be used in model studies, including a cost‐effectiveness study, to advise the Dutch Ministry of Public Health in deciding whether cervical screening should be based on combined hrHPV and cytology testing instead of cytology alone. Between January 1999 and September 2002, 44,102 women (mean age = 42.8 years; range = 29–61) that participated in the regular Dutch screening program were included in our study. In the Intervention Group the distribution of cytology and hrHPV by cytology class was as follows: normal cytology 96.6% (3.6% hrHPV positive); borderline and mild dyskaryosis (BMD) 2.5% (34.6% hrHPV positive); and moderate dyskaryosis or worse (>BMD) 0.8% (88.3% hrHPV positive), i.e., 0.4% moderate dyskaryosis (82.9% hrHPV positive), 0.3% severe dyskaryosis (92.5% hrHPV positive), 0.1% carcinoma in situ (95.2% hrHPV positive), <0.1% suspected for invasive cancer (hrHPV positive 100.0%). In the Control Group 96.5% of the women had normal cytology, 2.4% BMD and 0.8% >BMD, i.e., 0.4% moderate dyskaryosis, 0.3% severe dyskaryosis, 0.1% carcinoma in situ, <0.1% suspected for invasive cancer. The presence of hrHPV was age‐dependent, decreasing from 12.0% at 29–33 years to 2.4% at 59–61 years. Among women with a positive hrHPV test, the prevalence of BMD was age‐dependent ranging from 20.2% at 29–33 years to 7.8% at 54–58 years. In contrast, the risk of >BMD of 13.7% among women with a positive hrHPV test was not age‐dependent. Our study indicates that large‐scale hrHPV testing by GP5+/6+ PCR‐EIA in the setting of population‐based cervical screening is practically feasible, is accepted by both participating women and general practitioners and yields highly reproducible results. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,538
Self-citation2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
Wright, Jr. (2002) · JAMA · doi:10.1001/jama.287.16.2120 · Cited by 1,215
Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia
Ho, G. Y. F., Burk, R. D., Klein, S., Kadish, A. S., Chang, C. J., Palan, P., Basu, J., Tachezy, R., Lewis, R., & Romney, S. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.18.1365 · Cited by 803
Nobbenhuis, M. A., Walboomers, J. M., Helmerhorst, T. J., Rozendaal, L., Remmink, A. J., Risse, E. K., van der Linden, H. C., Voorhorst, F. J., Kenemans, P., & Meijer, C. J. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12490-x · Cited by 685
Self-citationMeta-analysis of Pap Test Accuracy
Fahey, M. T., Irwig, L., & Macaskill, P. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117485 · Cited by 684
Manos, M. M., Kinney, W. K., Hurley, L. B., Sherman, M. E., Shieh-Ngai, J., Kurman, R. J., Ransley, J. E., Fetterman, B. J., Hartinger, J. S., McIntosh, K. M., et al. (1999) · JAMA · doi:10.1001/jama.281.17.1605 · Cited by 568
Jacobs, M. V., Snijders, P. J., van den Brule, A. J., Helmerhorst, T. J., Meijer, C. J., & Walboomers, J. M. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.791-795.1997 · Cited by 568
Self-citationSchiffman, M., Herrero, R., Hildesheim, A., Sherman, M. E., Bratti, M., Wacholder, S., Alfaro, M., Hutchinson, M., Morales, J., Greenberg, M. D., et al. (2000) · JAMA · doi:10.1001/jama.283.1.87 · Cited by 540
Clavel, C., Masure, M., Bory, J.-P., Putaud, I., Mangeonjean, C., Lorenzato, M., Nazeyrollas, P., Gabriel, R., Quereux, C., & Birembaut, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1845 · Cited by 465
Cited by
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Self-citationde Sanjosé, S., Diaz, M., Castellsagué, X., Clifford, G., Bruni, L., Muñoz, N., & Bosch, F. X. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70158-5 · Cited by 1,669
Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.10897 · Cited by 1,409
Cuzick, J., Clavel, C., Petry, K., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21955 · Cited by 1,141
Self-citationHuman Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Naucler, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073204 · Cited by 797
Bulkmans, N., Berkhof, J., Rozendaal, L., van Kemenade, F., Boeke, A., Bulk, S., Voorhorst, F., Verheijen, R., van Groningen, K., Boon, M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61450-0 · Cited by 637
Self-citationRijkaart, D. C., Berkhof, J., Rozendaal, L., van Kemenade, F. J., Bulkmans, N. W., Heideman, D. A., Kenter, G. G., Cuzick, J., Snijders, P. J., & Meijer, C. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70296-0 · Cited by 515
Self-citationBead-Based Multiplex Genotyping of Human Papillomaviruses
Schmitt, M., Bravo, I. G., Snijders, P. J. F., Gissmann, L., Pawlita, M., & Waterboer, T. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.504-512.2006 · Cited by 482
Self-citationHPV‐mediated cervical carcinogenesis: concepts and clinical implications
Snijders, P. J., Steenbergen, R. D., Heideman, D. A., & Meijer, C. J. (2006) · The Journal of Pathology · doi:10.1002/path.1866 · Cited by 455
Self-citationAge-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review
Smith, J. S., Melendy, A., Rana, R. K., & Pimenta, J. M. (2008) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2008.07.009 · Cited by 377
Melnikow, J., Henderson, J. T., Burda, B. U., Senger, C. A., Durbin, S., & Weyrich, M. S. (2018) · JAMA · doi:10.1001/jama.2018.10400 · Cited by 302
Gok, M., Heideman, D. A. M., van Kemenade, F. J., Berkhof, J., Rozendaal, L., Spruyt, J. W. M., Voorhorst, F., Belien, J. A. M., Babovic, M., Snijders, P. J. F., et al. (2010) · BMJ · doi:10.1136/bmj.c1040 · Cited by 293
Self-citationNaucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., Radberg, T., Strander, B., Forslund, O., Hansson, B.-G., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn444 · Cited by 287
Tota, J. E., Chevarie-Davis, M., Richardson, L. A., deVries, M., & Franco, E. L. (2011) · Preventive Medicine · doi:10.1016/j.ypmed.2011.08.017 · Cited by 261
Leinonen, M., Nieminen, P., Kotaniemi-Talonen, L., Malila, N., Tarkkanen, J., Laurila, P., & Anttila, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp367 · Cited by 259
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer
Wilting, S. M., van Boerdonk, R. A., Henken, F. E., Meijer, C. J., Diosdado, B., Meijer, G. A., le Sage, C., Agami, R., Snijders, P. J., & Steenbergen, R. D. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-167 · Cited by 258
Self-citationvon Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., Suonio, E., et al. (2015) · Papillomavirus Research · doi:10.1016/j.pvr.2015.06.006 · Cited by 253
Importance of HPV Genotyping for the Screening, Therapy and Management of Cervical Neoplasias.
Jentschke, M., Soergel, P., & Hillemanns, P. (2012) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0032-1314959 · Cited by 35
Summerer, D., Hevroni, D., Jain, A., Oldenburger, O., Parker, J., Caruso, A., Stähler, C. F., Stähler, P. F., & Beier, M. (2010) · New Biotechnology · doi:10.1016/j.nbt.2010.03.005 · Cited by 12
Metadata
- Authors
- Bulkmans, N. W. J., Rozendaal, L., Snijders, P. J. F., Voorhorst, F. J., Boeke, A. J. P., Zandwijken, G. R. J., van Kemenade, F. J., Verheijen, R. H. M., v Groningen, K., Boon, M. E., Keuning, H. J. F., van Ballegooijen, M., van den Brule, A. J. C., & Meijer, C. J. L. M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-02-09
- Volume
- 110
- Issue
- 1
- Pages
- 94-101
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2009256930
- Cited by
- 269
- References
- 32
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.